Vertaling van "reported the table gives " (Nederlands → Frans) :

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

They aim to highlight the impact of reports on suicides, to provide reliable sources of information, to give suggestions about how to report on suicides both in general and in specific circumstances and to point out which pitfalls to avoid when reporting on suicide.
Ces indications ont pour but de mettre en évidence l’impact des reportages sur le suicide, d’indiquer les sources d’information fiables, de suggérer comment rapporter le suicide aussi bien dans des circonstances générales que spécifiques, et de préciser les pièges à éviter dans un reportage sur le suicide.

Reactions and events reported in 2006 were analysed and summarized in a first annual report which gives an overview of the notifications, the most important findings and a number of recommendations ●● In 2007 a total of 848 reactions and events
Reactions and events reported in 2006 were analysed and summarized in a first annual report which gives an overview of the notifications, the most important findings and a number of recommendations ●● In 2007 a total of 848 reactions and events

This report attempts to give a survey of existing research on these questions, to draw a list of all that already exists in the field of prevention and assistance, and, based on this information, to provide an overview of the recommendations on which the experts of the working group have agreed. − 4 −
Ce rapport tente de donner un aperçu des recherches existantes sur ces questions, d’inventorier ce qui existe déjà en matière de prévention et de prise en charge et enfin, sur ces différentes bases, de dresser un tableau des recommandations sur lesquelles les experts du groupe de travail se sont entendus.

Table 2: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words
Table 4: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words

Table 3: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)
Table 5: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)

In a report of 15 January 2009, the European Food Safety Authority (EFSA) gives its opinion about the innocuousness of taurine and D-glucuronolactone as individual ingredients of energy drinks. This is based on new data from the literature and recent studies by the same applicant (EFSA, 2009).
Enfin, dans un rapport du 15 janvier 2009, l’European Food Safety Authority (EFSA) se prononce sur l’innocuité de la taurine et de la D-glucuronolactone en tant qu’ingrédients individuels de boissons énergisantes en se fondant sur les données récentes de la littérature et de nouvelles études fournies par le même pétitionnaire mais ne procède pas à une évaluation de l’innocuité de ces boissons en tant que telles (EFSA, 2009).

NEW ETSC PIN REPORT:Goods and passenger transport vehicles give reason for concern despite drop in deaths 30-04-2013
NEW ETSC PIN REPORT:Goods and passenger transport vehicles give reason for concern despite drop in deaths 30/04/2013

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)